BLUEPRINT MEDICINES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.85 USD | -2.31% |
|
-0.46% | -5.84% |
Financials (USD)
| Sales 2024 * | 393M | Sales 2025 * | 599M | Capitalization | 5.44B |
|---|---|---|---|---|---|
| Net income 2024 * | -340M | Net income 2025 * | -161M | EV / Sales 2024 * | 13.5 x |
| Net cash position 2024 * | 129M | Net cash position 2025 * | 38.44M | EV / Sales 2025 * | 9.02 x |
| P/E ratio 2024 * |
-16
x | P/E ratio 2025 * |
-34.6
x | Employees | 655 |
| Yield 2024 * |
-
| Yield 2025 * |
1.12% | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Blueprint Medicines Corporation
More recommendations
More press releases
More news
| 1 day | +0.59% | ||
| 1 week | -3.63% | ||
| Current month | -6.28% | ||
| 1 month | +2.40% | ||
| 3 months | +11.57% | ||
| 6 months | +82.85% | ||
| Current year | -3.62% |
1 week
84.33
91.76
1 month
84.3397.00
Current year
72.24101.00
1 year
43.89101.00
3 years
37.82117.86
5 years
37.82125.61
10 years
13.04125.61
| Managers | Title | Age | Since |
|---|---|---|---|
Kathryn Haviland
CEO | Chief Executive Officer | 48 | 16-01-04 |
Alexis Borisy
FOU | Founder | 52 | 08-09-30 |
| Director of Finance/CFO | 52 | 14-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lynn Seely
BRD | Director/Board Member | 65 | 16-04-13 |
Alexis Borisy
FOU | Founder | 52 | 08-09-30 |
Lonnel Coats
BRD | Director/Board Member | 58 | 16-02-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.39% | 0 M€ | 0.00% | - | |
| 0.24% | 0 M€ | 0.00% | - | |
| 0.18% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 86.85 | -2.31% | 813 144 |
| 24-04-18 | 88.9 | +0.59% | 734,936 |
| 24-04-17 | 88.38 | +2.66% | 728,290 |
| 24-04-16 | 86.09 | +1.07% | 410,709 |
| 24-04-15 | 85.18 | -2.37% | 506,386 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
88.9
USD
Average target price
97.38
USD
Spread / Average Target
+9.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.62% | 5.44B | |
| -1.82% | 41.35B | |
| +42.04% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- BPMC Stock
